Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：1

作者：

Akula, Vinita ^{[1
]}

Chen, Lily ^{[1
]}

Acikgoz, Yusuf ^{[2
]}

Klein, Katherine ^{[1
]}

Yavuz, Betul Gok ^{[3
]}

Cevik, Lokman ^{[4
]}

Demir, Tarik ^{[5
]}

Manne, Ashish ^{[2
]}

Sahin, Ilyas ^{[6
]}

Kaseb, Ahmed ^{[7
]}

Hasanov, Elshad ^{[2
]}

机构：

[1] Univ Texas, Dept Internal Med, Hlth Sci Ctr, Houston UTHealth, Houston, TX USA

[2] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[3] Univ Missouri, Dept Med, Columbia, MO USA

[4] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH USA

[5] Northwestern Univ, Div Hematol & Oncol Dev Therapeut Inst, Chicago, IL USA

[6] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA

[7] Univ Texas, Dept Gastrointestinal Med Oncol, MD Anderson Canc Ctr, Houston, TX USA

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

CAMRELIZUMAB PLUS APATINIB; OPEN-LABEL; DOUBLE-BLIND; SINGLE-ARM; RECURRENCE; RESECTION; SORAFENIB; CANCER; TRIAL; HCC;

D O I：

10.1038/s41698-025-00846-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

页数：13

共 50 条

[21] Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma
Tuersun, Adili
Yasen, Yadikaer
Mohetaer, Munire
Hou, Guanxin
Cheng, Gang
Zhao, Xin
FRONTIERS IN MEDICINE, 2025, 11
[22] Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
Cui, Tian-ming
Liu, Yao
Wang, Jia-bei
Liu, Lian-xin
ONCOTARGETS AND THERAPY, 2020, 13 : 11725 - 11740
[23] Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates
Shek, Dmitrii
Read, Scott A.
Nagrial, Adnan
Carlino, Matteo S.
Gao, Bo
George, Jacob
Ahlenstiel, Golo
ONCOLOGIST, 2021, 26 (07) : E1216 - E1225
[24] The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Leone, Patrizia
Solimando, Antonio Giovanni
Fasano, Rossella
Argentiero, Antonella
Malerba, Eleonora
Buonavoglia, Alessio
Lupo, Luigi Giovanni
De Re, Valli
Silvestris, Nicola
Racanelli, Vito
VACCINES, 2021, 9 (05)
[25] Immune checkpoint inhibitors for hepatocellular carcinoma-A game changer in treatment landscape
Liu, Tsung-Hao
Shen, Ying-Chun
Cheng, Ann-Lii
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (08) : 1371 - 1383
[26] Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
De Stefano, Nicola
Patrono, Damiano
Colli, Fabio
Rizza, Giorgia
Paraluppi, Gianluca
Romagnoli, Renato
CANCERS, 2024, 16 (13)
[27] Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
Marron, Thomas U.
Schwartz, Myron
Corbett, Virginia
Merad, Miriam
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 571 - 581
[28] Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
D'Alessio, Antonio
Stefanini, Bernardo
Blanter, Julia
Adegbite, Benjamin
Crowley, Fionnuala
Yip, Vincent
Slater, Sarah
Fulgenzi, Claudia Angela Maria
Celsa, Ciro
Manfredi, Giulia Francesca
Pai, Madhava
Goldin, Robert
Ward, Stephen C.
Fiel, Maria Isabel
Shu, Daniel H.
Su, Yung-Yeh
Cortellini, Alessio
Baretti, Marina
Anders, Robert
Yarchoan, Mark
Hsu, Chiun
Marron, Thomas U.
Pinato, David J.
LANCET ONCOLOGY, 2024, 25 (11) : 1465 - 1475
[29] Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
Liu, Ziyu
Lin, Yan
Zhang, Jinyan
Zhang, Yumei
Li, Yongqiang
Liu, Zhihui
Li, Qian
Luo, Ming
Liang, Rong
Ye, Jiazhou
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
[30] Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
Abushukair, Hassan Mohammed
Saeed, Anwaar
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (06) : 1210 - 1212

← 1 2 3 4 5 →